Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis

NCT00506792 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: QAU145
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals